Apple board member, Arthur Levinson, has joined the board of Amyris Biotechnologies, Inc.
He’s joining to pursue what appears to potentially be a green vision, saying, “Amyris’s technology of turning microbes into living factories to produce defined, recoverable, high energy molecules offers an exciting potential alternative to petroleum,” said Levinson.
“I’m looking forward to working with the board and management to seek to realize their vision of reducing carbon emissions to better our environment.”
“Arthur is a highly respected business and technology leader who led one of the most important and successful science-based companies in the world,” said John Melo, chief executive officer of Amyris. “His experience will add immeasurably to our leadership team, and will help guide us as we work to capitalize on the potential of our industrial synthetic biology platform.”
Levinson is no stranger to biotechnology.
He served as Genentech CEO from 1995 to 2009, and as chairman of Genentech since 1999. Levinson joined Genentech in 1980 as a research scientist. He became vice president of research technology in 1989, vice president of research in 1990, senior vice president of research in 1992 and senior vice president of research and development in 1993.
Levinson is a director of Apple and a director of NGM Biopharmaceuticals, Inc.
He also serves on the Board of Scientific Consultants of the Memorial Sloan-Kettering Cancer Center, on the Industrial Advisory Board of the California Institute for Quantitative Biomedical Research, on the Advisory Council for the Princeton University Department of Molecular Biology, on the Advisory Council for the LewisSigler Institute for Integrative Genomics, and on the Executive Council of TechNet.